By Fineline Cube The National Drug Alliance Procurement Office has revoked the Volume-Based Procurement (VBP) winning bid qualifications of three drugs and imposed unprecedented penalties on four pharmaceutical firms for failure to fulfill supply obligations—marking the strictest enforcement action in VBP history.
The affected products include dopamine (Beijing Fu Kang Ren Bio-pharm Tech), dapagliflozin (Hetero Labs Limited), and methocarbamol (Guangzhou Hehe Pharmaceutical), along with its contract manufacturer, Chengdu Tiantaishan Pharmaceutical. All four companies have been blacklisted from future VBP rounds, with bans ranging from 18 months to four years.
Enforcement Summary
| Company | Product | VBP Round Won | Penalty Period | Reason |
|---|---|---|---|---|
| Beijing Fu Kang Ren Bio-pharm | Dopamine | Round 9 | 03 Apr 2026 – 02 Apr 2030 | Failed to supply contracted volumes despite follow-up |
| Hetero Labs Limited | Dapagliflozin | Round 11 | 03 Apr 2026 – 02 Apr 2030 | Same as above |
| Guangzhou Hehe Pharmaceutical | Methocarbamol | — | 02 Apr 2026 – 01 Oct 2027 | Supply chain failure (with CMO) |
| Chengdu Tiantaishan Pharma | (CMO for methocarbamol) | — | 02 Apr 2026 – 01 Oct 2027 | Co-responsible for non-delivery |
Background & Regulatory Context
- VBP Program: China’s cornerstone drug pricing reform, covering >90% of public hospital procurement volume for selected generics and off-patent drugs
- Winning Bid Obligation: Awardees must guarantee continuous, nationwide supply at the bid price for the entire contract period (typically 2–3 years)
- Escalation Process: The Procurement Office conducted multiple rounds of remedial discussions before imposing penalties, citing “persistent inability to meet institutional demand”
- Precedent: Previous violations resulted in 6–12 month suspensions; this four-year ban signals a hardening stance on supply reliability
Market & Strategic Implications
- Immediate Impact: Hospitals must source dopamine and dapagliflozin from higher-priced backup suppliers, potentially increasing short-term costs
- Reputational Risk: Blacklisted firms face exclusion not only from VBP but also from provincial tenders and hospital formularies that reference national lists
- Investor Caution: Foreign generic manufacturers (e.g., Hetero Labs, India) now face heightened scrutiny over China-specific supply chain resilience
- Policy Signal: Authorities prioritize supply security over lowest price, reinforcing that VBP is not just a cost-cutting tool but a national essential medicines assurance mechanism
Forward-Looking Statements
This brief reflects official regulatory actions as of 07 Apr 2026. Future participation eligibility remains subject to compliance verification by Chinese health authorities.-Fineline Info & Tech